ArticleJournal of hematology & oncology2023

Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2.

Sara Pusceddu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.